On June 20, 2019, Autotelic Bio Co., Ltd. entered into a contract with

MRC(Medical research center for Cancer) of Chungbuk National University to acquire the patent right

for a targeted therapeutic anti-cancer new drug candidate (under development with a name of “ATB-310”).

K284-6111, an anti-cancer new drug candidate, was selected as a next-generation targeted anticancer drug

selected from 14 million candidate substances using the big data AI.

Autotelic Bio plans to carry out non-clinical studies including toxicity tests

after initial studies such as drug efficacy test and pharmacological test in various carcinomas including lung cancer.

Following the development of the immuno-anticancer drug ATB-301,

the acquisition of the new drug candidate for the targeted anticancer drug will greatly contribute

to the growth of Autotelic bio as a biotechnology company specializing in the development

of innovative anti-cancer new drugs through the expansion of the pipeline.